Accéder au contenu
Merck
Toutes les photos(1)

Documents

878119C

Avanti

C16 Lyso PAF

Avanti Research™ - A Croda Brand 878119C

Synonyme(s) :

1-O-hexadecyl-2-hydroxy-sn-glycero-3-phosphocholine

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C24H52NO6P
Numéro CAS:
52691-62-0
Poids moléculaire :
481.65
Code UNSPSC :
12352211
Nomenclature NACRES :
NA.25

Forme

liquid

Conditionnement

pkg of 1 × 1 mL (878119C-5mg)

Fabricant/nom de marque

Avanti Research™ - A Croda Brand 878119C

Concentration

5 mg/mL (878119C-5mg)

Type de lipide

bioactive lipids
phosphoglycerides

Conditions d'expédition

dry ice

Température de stockage

−20°C

Chaîne SMILES 

O[C@](COP([O-])(OCC[N+](C)(C)C)=O)([H])COCCCCCCCCCCCCCCCC

InChI

1S/C24H52NO6P/c1-5-6-7-8-9-10-11-12-13-14-15-16-17-18-20-29-22-24(26)23-31-32(27,28)30-21-19-25(2,3)4/h24,26H,5-23H2,1-4H3/t24-/m1/s1

Clé InChI

VLBPIWYTPAXCFJ-XMMPIXPASA-N

Description générale

1-O-hexadecyl-sn-glycero-3-phosphocholine (C16:0 lyso PAF) is a precursor and metabolite of 1-O-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (C16:0 PAF). Increased levels of C16:0 lyso-PAF has been observed in temporal cortex of Alzheimer disease patients. Lyso-PAF is synthesized from 1-O-alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine (1-alkyl-phosphatidylcholine) by the enzyme phospholipase A2 in the remodeling pathway.

Application

C16 Lyso PAF or 1-O-hexadecyl-sn-glycero-3-phosphocholine has been used as a substrate of lysoplasmalogen (LysoPls)-specific phospholipase D (lysophospholipase D (LysoPLD) in an experimental assay. It has also been used as an authentic standard for generating standard curves for quantification of lipid analytes.

Conditionnement

5 mL Clear Glass Sealed Ampule (878119C-5mg)

Informations légales

Avanti Research is a trademark of Avanti Polar Lipids, LLC

Pictogrammes

Skull and crossbonesHealth hazard
GHS06,GHS08

Mention d'avertissement

Danger

Classification des risques

Acute Tox. 3 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 3 - Carc. 2 - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - STOT RE 1 - STOT SE 3

Organes cibles

Central nervous system, Liver,Kidney

Code de la classe de stockage

6.1D - Non-combustible acute toxic Cat.3 / toxic hazardous materials or hazardous materials causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

does not flash

Point d'éclair (°C)

does not flash

Certificats d'analyse (COA)

Recherchez un Certificats d'analyse (COA) en saisissant le numéro de lot du produit. Les numéros de lot figurent sur l'étiquette du produit après les mots "Lot" ou "Batch".

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Scott D Ryan et al.
Proceedings of the National Academy of Sciences of the United States of America, 106(49), 20936-20941 (2009-11-21)
Perturbation of lipid second messenger networks is associated with the impairment of synaptic function in Alzheimer disease. Underlying molecular mechanisms are unclear. Here, we used an unbiased lipidomic approach to profile alkylacylglycerophosphocholine second messengers in diseased tissue. We found that
Hideo Shindou et al.
The Journal of biological chemistry, 282(9), 6532-6539 (2006-12-22)
Platelet-activating factor (PAF) is a potent proinflammatory lipid mediator eliciting a variety of cellular functions. Lipid mediators, including PAF are produced from membrane phospholipids by enzymatic cascades. Although a G protein-coupled PAF receptor and degradation enzymes have been cloned and
Saki Yamaura et al.
Clinica chimica acta; international journal of clinical chemistry, 481, 184-188 (2018-03-20)
Measurement of lipoprotein-associated phospholipase A2 (Lp-PLA2) can be used as an adjunct to traditional cardiovascular risk factors for identifying individuals at higher risk of cardiovascular events. This can be performed by quantification of the protein concentration using an ELISA platform
Kelsey B Law et al.
Autophagy, 13(5), 868-884 (2017-05-20)
Peroxisome biogenesis disorders (PBDs) are metabolic disorders caused by the loss of peroxisomes. The majority of PBDs result from mutation in one of 3 genes that encode for the peroxisomal AAA ATPase complex (AAA-complex) required for cycling PEX5 for peroxisomal
Michael A Kennedy et al.
PLoS genetics, 10(1), e1004010-e1004010 (2014-01-28)
Unbiased lipidomic approaches have identified impairments in glycerophosphocholine second messenger metabolism in patients with Alzheimer's disease. Specifically, we have shown that amyloid-β42 signals the intraneuronal accumulation of PC(O-16:0/2:0) which is associated with neurotoxicity. Similar to neuronal cells, intracellular accumulation of

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique